Background: Recent clinical evidence indicates that an intradermal (ID) delivery of vaccines confers superior immunogenicity as compared to a standard intramusclular or subcutaneous (SC) delivery. Methods: In this exploratory study, 600 healthy adults were randomized to 6 study groups with subgroups of young adults (20-64 years old) and older adults (65 years and older). The subjects were either injected by a novel ID injection system with a single dose of 6, 9, or 15 g HA or two doses (21 days apart) of 15 g HA per strain or injected by an SC injection method with a single or two doses (21 days apart) of 15 g HA per strain. Immunogenicity was assessed using hemagglutination inhibition (HAI) titer and microneutralization titer on Days 0, 10, 21, and 42. Solicited and unsolicited adverse events were recorded for 7 and 21 days post-vaccination, respectively. Results: In both young adults and older adults groups, the geometric titer (GMT) ratios of HAI in the ID 15 g HA group were higher than those in the SC 15 g HA group on both Day 10 and Day 21, while those in the ID 6 and ID 9 g HA groups were comparable with those in the SC 15 g HA group. The kinetics of GMTs of HAI suggested that the ID vaccine has the potential to induce the prompt immune response, which is rather hampered in older adults as seen in the SC vaccine groups. The injection-site AEs were generally mild and transient, and did not occur in a dose or dosage-dependent manner. Conclusions: The results of this study clearly suggest that the immunologic profile of the ID vaccine is better than that of the SC vaccine, while the safety profile of the ID vaccine is similar to that of the SC vaccine. In this exploratory study with almost 100 subjects per each group, single or two-dose administration of the ID vaccine containing 15 g HA was suggested to be an appropriate regimen in order to prevent influenza and to reduce the associated disease burden.
Introduction
Influenza remains a significant cause of morbidity and mortality worldwide, resulting in a major public health concern. Despite preventive efforts, seasonal influenza virus infections are estimated to cause 3-5 million cases of severe illness and up to 250,000-500,000 deaths every year worldwide [1] . It is still difficult to control Abbreviations: ID, intradermal; SC, subcutaneous; HA, hemagglutinin; HAI, hemagglutination inhibition; NT, microneutralization; GMT, geometrical mean titer; GMTR, GMT ratio; SCR, seroconversion ratio; SPR, seroprotection ratio; AE, adverse event; CHMP, The Committee for Medicinal Products for Human Use.
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influenza outbreaks, epidemics, and/or pandemics, because of the nature of influenza viruses, such as the antigenic drift occurring every season, changes of host/tissue tropism from natural reservoirs, i.e. transmission from swine and/or birds to humans, and the high transmissibility due to the short incubation period to reproduce infectious viruses [2] . In order to prevent from influenza virus infection and to reduce the burden of influenza-associated diseases, vaccination strategies have been implemented and cover children 6 months and older, adolescents, young adults, and the elderly [1] . Standard influenza vaccines currently used contain the tri-or quadri-valent hemagglutinin (HA) antigen derived from inactivated influenza virus and are administered either intramuscularly (IM) or subcutaneously (SC), the latter being used exclusively in Japan. The number of doses and dosage of vaccines vary depending on the age, underlying diseases, and conditions of the vaccinee [1] . In Japan, the http://dx.doi.org/10.1016/j.vaccine.2015.09.010 0264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4. 0/). recommended number of doses for the seasonal influenza vaccine is one or two doses for 13 years and older. Among target populations, the elderly, in general, need to securely acquire the protective immunity because they are more vulnerable to death and hospitalization due to influenza and at higher risk of deterioration from underlying diseases upon influenza infection as compared with healthy young adults [1] . Standard influenza vaccines have, however, a lower immunogenicity in the elderly than in young adults [3] .
In order to improve influenza vaccine efficacy, various approaches have been made over decades, including the change of administration route, i.e., intradermal, transdermal, or intranasal route, and the change of formulation, i.e., addition of new adjuvants, an increase of the antigen dosage, or the usage of different antigen types. Among these, it has been clinically demonstrated that influenza vaccines delivered by several different types of intradermal (ID) injection and those formulated with a novel adjuvant have unique profiles in immunogenicity and usability superior to the standard ones and some of such products have been introduced into the market since the late 2000s [4] [5] [6] .
Accumulating evidence has indicated that the immunogenicity of vaccines is modulated depending on the route of administration. ID vaccination has the advantages of immunogenicity, safety, tolerability, and acceptability over IM or SC vaccination [4, 7] . In fact, as a dose-sparing, the World Health Organization (WHO) recommend the ID administration of a reduced dosage of the rabies vaccine originally used for the IM injection with an expectation to improve vaccination coverage for post-exposure prophylaxis in low-income countries [8] . However, thus far, the ID delivery has been used as a route for limited licensed vaccines, including Bacillus Calmette-Guérin (BCG) for tuberculosis and a new type of influenza HA vaccine with an injection device specifically for the ID delivery [4, 7] .
The accuracy and the consistency of an ID administration by the Mantoux technique with a standard syringe and needle mostly depend on the performance of the practitioner. In order to offer a simple, accurate, consistent, and safe ID administration, several different devices specifically for the ID injection have been developed [4, [9] [10] [11] [12] .
In this exploratory dose-finding study, we investigated the immunogenicity and safety of two different numbers of doses (single and two-dose) and three different dosages (6, 9, and 15 g HA per dose) of the influenza vaccine with the novel ID injection system (Immucise®, Terumo Co., Tokyo, Japan) by comparing it with the standard SC vaccine (15 g HA per dose). As a result, we have decided the number of doses and dosage of the novel ID vaccine appropriate for clinical use and will further examine its efficacy and safety profile in the confirmatory studies and its application for infants and adolescents.
Materials and methods

Study design and objectives
This phase 1/2, randomized, active control, parallel-group study was conducted at four centers in Japan in 2013. The objective of this study was an evaluation of the number of doses and dosage of the novel ID vaccine by comparing it with the standard SC injection type seasonal influenza vaccine in healthy adults aged 20 years old and older.
The randomization lists were prepared by using a permuted block randomization method. Six hundred subjects were randomized at an equal ratio to the four different groups for the ID vaccine (single-dose of 6, 9, or 15 g HA and two-dose of 15 g HA) and the two different groups for the SC vaccine (single-dose or two-dose of 15 g HA). The ratio of 20-to 64-year-old subjects (Young Adult subgroup) to 65 years and older subjects (Older Adult subgroup) was 1:1 in each vaccine group. The ID vaccine groups of single-dose 6, 9, and 15 g HA were double-blinded.
On Day 0, blood was taken and then the first vaccination was conducted in all groups. On Day 10 (7-13 days after the first vaccination), blood was taken in the single-dose groups. On Day 21 (14-28 days after the first vaccination), blood was taken in all groups and then the second vaccination was conducted in the twodose groups. On Day 42 (14-28 days after the second vaccination), blood was taken in the two-dose groups. The appearance of shock and anaphylaxis was checked in all groups up to 30 min after each vaccination.
This study was approved by the institutional review boards of each study center. The study was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. Written informed consent was obtained from all subjects before enrollment.
Subjects
Healthy Japanese adults aged 20 years and older were eligible to participate in this study. The main exclusion criteria included: any history of seasonal influenza in the past six months, any history of seasonal influenza vaccination in the past six months, an axillary temperature ≥37.5 • C, severe acute illness, any history of intolerance or anaphylaxis to the study vaccine components or the ID injection system, and past medical history of diseases which were described as severe AEs (e.g. acute disseminated encephalomyelitis and thrombocytopenia purpura).
Vaccines
All vaccines contain inactivated, trivalent, split-virion influenza hemagglutinin (HA) derived from A/California/7/2009/ (H1N1)pdm09, A/Victoria/361/2011(H3N2), and B/Wisconsin/ 1/2010 vaccine strains recommended by the Ministry of Health, Labor, and Welfare in Japan for the 2012/13 season. All vaccines were manufactured by using embryonated eggs at Kitasato Daiichi Sankyo Vaccine Co., Ltd (Saitama, Japan). The ID vaccine was administrated with a dose of 0.1 mL containing 6, 9, or 15 g of HA per strain per dose using the ID injection system (Immucise ® , Terumo Co., Tokyo, Japan). The ID injection system consists of a needle assembly with a single 33-gauge needle and a syringe. As a control, the licensed influenza vaccine was administered as an SC dose of 0.5 mL containing 15 g of HA per strain per dose. The ID vaccine was administrated in the deltoid area of the upper arm, while the SC vaccine was administrated into an extensor side of the upper arm.
Immunogenicity assessment
Immunogenicity was assessed using hemagglutination inhibition (HAI) titers and microneutralization (NT) titers in a blinded manner. HAI titers were measured by using turkey red blood cells, while NT titers were measured by using each vaccine strain of influenza viruses. Both antibody titers were measured at VisMederi srl (Siena, Italy). HAI titer was defined as the reciprocal of the highest dilution at which hemagglutin (HA) activity was totally inhibited. The titer of each sample was calculated as the average of its duplicate. NT titers were determined as the reciprocal of the serum dilution at which at least 50% inhibition of cytopathogenic effect was achieved, and then calculated according to the Spearman-Kärber formula. Based on the criteria for seasonal influenza vaccine of The Committee for Medicinal Products for Human Use (CHMP), immunogenicity was assessed based on the geometric mean titer (GMT) of HAI, the seroprotection rate (SPR, the percentage of subjects with HAI titer ≥1:40), the seroconversion rate (SCR, the percentage of subjects with either a pre-vaccination HAI titer <1:10 and post-vaccination HAI titer ≥1:40 or a pre-vaccination HAI titers ≥1:10 and at least a 4fold increase in post-vaccination HAI titer), and the geometric mean titer ratio (GMTR) of post-vaccination titer to pre-vaccination titer of HAI [13] . NT titers were also assessed in the same way.
Immunogenicity was assessed in all subjects who received the vaccine.
Safety assessment
Solicited injection-site AEs (erythema, swelling, pruritus, hotness, pain, induration, and ecchymosis) and systemic AEs (malaise, headache, shivering, fever, and rash) were prelisted in the diary, and subjects were spontaneously checked every day up to 7 days following each vaccination. Unsolicited AEs and serious AEs (SAEs) were recorded throughout the study period (Days 0-21 for the single-dose group; Days 0-42 for the two-dose group). The severity of injection-site erythema, swelling, induration, and hemorrhage was graded by size (long-axis diameter) as mild (<2.0 cm), moderate (2.0-5.0 cm), or severe (>5.0 cm), while that of fever was graded as mild (37.5-37.9 • C), moderate (38.0-38.9 • C), or severe (≥39.0 • C). All other AEs were classified as mild (for no interference with daily activity and easily tolerated), moderate (for some interference with daily activity), or severe (for incapacitating condition). Safety was assessed in all subjects who received the first vaccination.
Statistical analysis
A total of 600 healthy adult subjects were enrolled into this study. The sample size was decided to be 50 subjects per subgroup (100 subjects per group with 50 for Young Adult subgroup and 50 for Older Adult subgroup). Statistical analyses were performed with SAS ® version 9.2 (SAS Institute, Cary, NC, USA).
Results
Study population
In April and May 2013, 600 subjects were enrolled. One hundred subjects were assigned to each group (50 for the Young Adult subgroup [20-64 years old] and 50 for the Older Adult subgroup [65 years old and older]) ( Fig. 1 ). After the first vaccination, 3 subjects in the Young Adult subgroups had withdrawn. Among these, 2 subjects had withdrawn voluntarily with one in the two-dose group of ID 15 g HA and another in the two-dose group of SC 15 g HA, while 1 subject had withdrawn due to moderate fever in the twodose group of ID 15 g HA. Also, after the first vaccination, 1 subject in the Older Adult subgroup had withdrawn in the two-dose group of ID 15 g HA because the investigator suspected angina pectoris and judged the subject as inadequate for continuing to join this clinical study.
The demography of subjects in this study is shown in Table 1 . The distribution of age, the sex ratio, and the frequency of those having history of seasonal influenza vaccination in the past two seasons (2011/12 and 2012/13) were comparable among the six vaccine groups. The coverage rates of seasonal influenza vaccination in Older Adult subgroups were higher than those in Young Adult subgroups. No subjects reported any history of seasonal influenza in the 2012/13 season.
Immunogenicity
As shown in Table 2 , the results of HAI titers in all ID vaccine groups met all parameters of the CHMP criteria for all three vaccine strains, except for the SPRs for the B strain in the single-dose Young Adult subgroup of ID 9 and ID 15 g HA.
Among the single-dose groups of ID 6, ID 9, and ID 15 g HA, and SC 15 g HA, the GMTs and GMTRs of HAI and the SCRs and SPRs of HAI titers for all three strains were the highest in the ID 15 g HA group on both Day 10 and Day 21, while the GMTRs of HAI were comparable among the ID 6, and ID 9 g HA groups, and Table 1 Demography of the study subjects.
Total
Single-dose group Two-dose group Total (n = 600) ID 6 g (n = 100) ID 9 g (n = 100) ID 15 g (n = 100) SC 15 g (n = 100) ID 15 g (n = 100) SC Data are for all vaccinated subjects. a Subjects who have previously received an influenza vaccination in the past 2 seasons (2011-2012, 2012-2013). Abbreviation: n, number of subjects. SC 15 g HA groups. This suggested that the ID vaccine containing 15 g HA induced higher serum HAI titers as compared with the standard SC 15 g HA vaccine and further suggested that the ID vaccines with a lower dose of HA, even as low as 6 g HA, induced HAI titers comparable with the standard SC 15 g HA vaccine.
The kinetics of the HAI titers after secondary vaccination on Day 21 showed that the boosting effect differed depending on the age of the subjects, the types of the vaccines, and the strains of HA antigens. In Older Adult subgroups, the GMTRs of HAI on Day 42 and Day 21 were comparable in the ID 15 g HA group except for in the B strain (the ratio of GMTR of Day 42 to that of Day A/H1N1, 1.07; A/H3N2, 1.07; B, 0.94) HA groups. Taken together, it was suggested that the ID vaccine has the potential to elicit the prompt immune response, which is rather hampered in older adults as seen in HAI titers induced by the standard SC vaccine in this study.
The SPRs for the H1N1 and H3N2 strains in both ID 15 g and SC 15 g HA groups achieved more than 90% on Day 21. In contrast, the highest difference of the SPRs between the groups of ID 15 g and SC 15 g HA was seen in the B strain in Older Adult subgroups (the SPR in the ID group versus that in the SC group [SPR ID vs SC] on Day 21: 62.00% vs 30.00% in the Older Adult subgroup, while 80.00% vs 78.00% in the Young Adult subgroup; SPR ID vs SC on Day 42: 69.39% vs 48.00% in the Older Adult subgroup, while 83.33% vs 75.51% in the Young Adult subgroup), suggesting that the advantages of the ID vaccine are apparent in subtype antigens showing lower immunogenicity, i.e., the B strain of influenza HA, and in lower responders, i.e., the elderly.
The results of NT titers are shown in Table 3 . As compared with HAI, the GMTRs of NT were lower, which may be due to a higher titer value in NT than that in HAI on Day 0 except for the H3N2 strain in Older Adult subgroups. The pattern of post-vaccination titer kinetics of NT was similar to that of HAI.
Safety
At least one unsolicited AE was reported in 531 subjects (in the single-dose groups: ID The frequencies of solicited injection-site AEs or systemic AEs are shown in Table 4 . The most frequently reported AEs in all groups were erythema, swelling, and pruritus at injection sites. a The European Union Committee for Medicinal Products forHuman Use (CHMP) criteria defined for people aged ≤60. Abbreviations: GMT, geometric mean titer; SCR, seroconversion rate (proportion with a pre-vaccination titer <1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer); GMTR, geometric mean titer ratio; SPR, seroprotection rate (percentage of participants with a post-vaccination titer ≥1:40); CI, confidence interval.
Table 2.2
Serological efficacy of hemagglutination inhibition antibody titer (older adults (65 years and older)).
Strain
Immunogenicity criteria a Day Single-dose group Two-dose group ID 6 g (n = 50) ID 9 g (n = 50) ID 15 g (n = 50) SC 15 g (n = 50) ID 15 g (n = 50) SC 15 g (n = 50)
A/H1N1 Injection-site erythema, swelling, and pruritus occurred more frequently, while injection-site pain occurred less frequently in the ID vaccine groups than the SC vaccine groups. The frequencies of solicited systemic AEs were comparable between the ID and the SC vaccine groups, with the most frequent ones being malaise and headache.
Among the single-dose ID vaccine groups with different dosages, the frequencies of any AE were comparable and were not in a dose-dependent fashion. In the two-dose ID vaccine group, the frequencies of any AE after the first vaccination (93.0% [93/100]) were comparable with those after the second vaccination (89.7% [87/97]). There were no apparent differences in the frequency of each AE between Young Adult and Older Adult subgroups (data not shown).
The ratios of each grade of injection-site erythema, swelling, and induration are shown in Fig. 2 . The ratios of severe erythema and severe swelling in the ID vaccine groups were lower than those in the SC vaccine groups. The severe induration was observed in the ID 6 and 9 g HA groups but not in the ID and SC 15 g HA groups. Taken together, it was not suggested that the severity of AEs at the injection site depends on the number of doses or dosage of the ID vaccine.
Injection-site AEs lasted for 4.8-8.4 days (the single-dose groups: ID 6 g HA, 7.5 days; ID 9 g HA, 7.5 days; ID 15 g HA, 8.3 days; SC 15 g HA, 4.8 days; the two-dose groups: ID 15 g HA, 8.4 days; SC 15 g HA, 5.0 days). Although the injection-site AEs in the ID vaccine groups persisted longer than those in the SC vaccine groups, all AEs in the ID vaccine groups disappeared without any medical treatment.
All solicited and unsolicited systemic AEs were classified as mild or moderate except immunoglobulin A nephropathy. Three subjects experienced a total of four SAEs, and one SAE, immunoglobulin A nephropathy, in the ID 6 g HA vaccine group was considered related to the vaccination. One subject in the two-dose ID 15 g HA group withdrew due to moderate fever that occurred on Day 4.
Discussion
In this study, it was suggested that the immunologic profile of the ID vaccine is better than that of the SC vaccine, while safety profile of the ID vaccine is similar to that of the SC vaccine. In this phase 1/2 study conducted with almost 100 subjects per each group, by comparing with the standard SC injection type seasonal influenza vaccine, the novel ID vaccine containing 15 g HA was clinically demonstrated to induce faster serum antibody responses and the higher responses were maintained during the examination period up to 42 days after the first vaccination. The results in all the ID vaccine groups, including those even in the subgroup of Young Adult or Older Adult, met CHMP criteria for all three vaccine strains and were well tolerated. It was therefore suggested that the ID vaccine containing 15 g HA per dose per strain with a single or two-dose regimen is appropriate for clinical use as a novel seasonal influenza vaccine, and with an expectation of a superior protection against influenza and the reduction of the disease burden.
The SCRs and GMTRs in the single-dose groups of ID 6, and 9 g, and SC 15 g HA were comparable, suggesting that dose-sparing can be expected by shifting from the standard SC vaccine to the ID vaccine for cost-reduction and securing vaccine supply.
High antibody responses by the ID vaccine observed in this clinical study imply that the novel ID injection system delivered the vaccine formulation to the dermis accurately and consistently. According to previous reports, it has been demonstrated that the thickness of the skin varies marginally depending on age, sex, and race, while that varies significantly depending on the local site of the body, e.g., the skin is thicker in the supracapsular and the deltoid areas as compared with in the forearm area [14, 15] . The ID injection system used in this study has a needle 1.15 mm in length inserting perpendicularly into the skin. The needle length is specially designed based on the skin thickness studies to stay the proper depth for ID injection [14, 15] . In fact, even though it was not designated in the clinical study protocol, a preliminary observation of the wheal formation and absence of fluid leakage at the injection site, which are defined as the criteria for successful ID injection [16] , was conducted. As a result, the frequencies of the injection-site wheal formation soon after the ID vaccination were 96.4% and 98.0% in Young Adult and Older Adult subgroups, respectively and no leakage was observed in this study. The results of previous clinical studies using different types of ID devices or using a standard syringe and needle (the Mantoux technique) suggest that the frequencies of the successful ID delivery were lower than those observed in this study [16] [17] [18] . The novel ID injection system is designed simple enough to handle easily and is expected to reduce risks of damaging tissues, such as blood vessels and peripheral nerves, due to its thin and short needle.
The safety profile of our ID vaccine in this phase 1/2 study with 497 injections of the ID vaccine was similar to those of other types of ID vaccines as investigated in previous studies [16, [19] [20] [21] [22] [23] [24] [25] . The frequencies of most AEs at the injection site in the ID vaccine groups were higher than the SC vaccine groups, although injection-site AEs were generally mild, transient, and did not occur in a dose or dosage-dependent manner. The safety profile in Older Adult subgroups was comparable with that in Young Adult subgroups. The high incidence rate of the injection-site AEs may be because the vaccine-induced inflammatory reactions that occurred in the dermis, i.e., the antigen-delivery site of the ID vaccine, are more detectable from the skin surface as compared with those in the subcutis. Our in-house study using an animal model has suggested that although the changes of inflammatory reactions examined by the histopathological analysis were similar between the ID dosing and the SC dosing of the same amount of influenza HA, the local irritation scores examined based on the appearance of the skin were higher after the ID dosing than after the SC dosing (data not shown). Taken together, it is suggested that the safety of the novel ID vaccine is secured in adults aged 20 years and older, at least in this exploratory clinical study.
Conclusions
In this exploratory study with almost 100 subjects per each group, we found that the novel ID vaccine containing 15 g HA induced serum antibody responses higher than the standard SC vaccine containing 15 g HA, and its safety was well tolerated, suggesting that a single or two-dose of the ID vaccine with a dose of 15 g HA is an appropriate regimen for clinical use in order to protect from influenza infection and to reduce the associated disease burden.
